On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


MetAlert, Inc. (MLRT) In Strong Position Entering 2023 According to CEO Patrick Bertagna

  • MetAlert’s CEO, Patrick Bertagna, while appearing in an interview presented by Sequire Spotlight and hosted by Carmel Fisher, expressed his optimism for the new year while also sharing the company’s recent progress
  • He discussed the company’s core objective- increasing the quality of life, and longevity of people living with Alzheimer’s, dementia, and autism (“ADA”)
  • Bertagna also hinted at potential acquisitions by the company, attributing it to extensive efforts over the past couple of years to clean up its balance sheet
  • He noted that as MetAlert’s revenue per user continues to grow, its margins will increase, ultimately placing the company in a position to uplist

While appearing in an interview presented by Sequire Spotlight, and hosted by Carmel Fisher, MetAlert (OTC: MLRT) CEO Patrick Bertagna discussed the company’s recent progress and how well it is poised to enter the 2023 financial year. Of note was his optimism in the new products launched thus far, such as the patented GPS SmartSole, a hub for collecting and transmitting data to the cloud in real-time, and RoomMate, an alert system that detects and alerts caregivers about patient behaviors, without intruding into their privacy (https://ibn.fm/q8cML).

MetAlert, a developer of personal protective medical equipment and supplies and a pioneer in wearable GPS, human and asset tracking systems, has sought to offer viable solutions to individuals afflicted with Alzheimer’s, dementia, and autism (“ADA”). This commitment has informed its approach and the development of its products that have so far gone beyond location-sensitive health monitoring devices to include Concierge, Artificial Intelligence, and the Telehealth platform that allows access remotely to doctors and other health professionals on an as-needed basis.

According to Bertagna, most of its target market cannot use conventional technologies. Because of that, MetAlert has developed a suite of products and services that allow caregivers to provide excellent care to these patients by quickly and efficiently monitoring where they are and how they are doing, and allowing them to send their medical information to their doctors for easier care.

“It is really about increasing the quality of life, the longevity of people that are challenged,” he noted.

Bertagna also hinted at MetAlert’s possible uplisting, having brought on board a leading figure in the private equity and Mergers and Acquisitions (“M&A”) community. He mentioned that the company has a lot planned for the new year, including acquisitions resulting from extensive efforts to clean up its balance sheet over the past couple of years.

“We spent the last couple of years cleaning up our balance sheet. We got rid of all our variable convertible debt, so our balance sheet looks very clean and healthy,” Bertagna noted.

“We think we are very well poised to enter 2023,” he added.

MetAlert has had an strong start to the new year with its Canadian distributor launch of its SmartSole flagship product. Its management, starting with CEO Bertagna, is confident about the company’s continued prospects. Bertagna is optimistic that, as its revenue per user (“RPU”) continues to grow, its margins will increase, ultimately placing the company in a position to uplist.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

From Our Blog

Sigyn Therapeutics Inc. (SIGYD) CEO Discusses Opportunities to Treat Cancer and Drug-Resistant Pathogens in Letter to Shareholders

February 23, 2024

James A. Joyce, the Chairman and CEO of development-stage medical technology company Sigyn Therapeutics (OTCQB: SIGYD, SIGY), recently discussed the company’s opportunities, challenges, and decision-making processes in a letter to shareholders (https://ibn.fm/wGTqS). The company is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health: Sigyn Therapeutics designed […]

Rotate your device 90° to view site.